Novartis announces global partnership with Amgen to develop and commercialize pioneering …

(Thomson Reuters ONE via COMTEX) — Novartis International AG / Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. – The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer’s Disease (AD); Novartis’ oral therapy CNP520 will be the lead molecule – Novartis and Amgen also plan to co-develop and co-commercialize Amgen’s migraine portfolio, including fully human monoclonal antibody AMG 334 with first phase III data expected in 2017 – Partnership reinforces Novartis’ continued commitment to developing and bringing innovative neuroscience treatment options to patients Basel, September 1, 2015 – Novartis announced today that it has entered into a global collaboration with Amgen…


Link to Full Article: Novartis announces global partnership with Amgen to develop and commercialize pioneering …